National Cancer Plan

Baroness Swinburne Excerpts

Monday 9th February 2026 Lords Chamber

[Baroness Merron (Lab)]

That last point will, of course, be drawn to the attention of the usual channels. I too would welcome a debate on this. Noble Lords might wish to note that when they have an opportunity to suggest or apply for debates.

The noble Lord’s last point was about elimination of cancer. That is possible in some cases. I am glad that he mentioned cervical cancer. I mentioned in my answer to the noble Lord, Lord Bethell, that we have committed to catch-up HPV vaccination campaigns from this year, to eliminate cervical cancer by 2040. That is absolutely the right thing to do, and to introduce the Tobacco and Vapes Bill, which I hope will become an Act, to phase out smoking and reduce youth vaping, which can be a gateway to smoking. That will also reduce risk factors.

The noble Lord, Lord Patel, is always right to press us to go further. I understand that. This is a plan for the long term but with staging posts along the way. We have already made progress. For example, I was very pleased when we announced a trial called EDITH for breast cancer screening, to harness the benefits of AI, working with operatives for sped up and more accurate diagnoses. This is one example and is to the point that the noble Baroness, Lady Walmsley, raised about AI.

I hear what the noble Lord says about cancer centres. We are seeking to move treatment and diagnosis from hospitals to community. That is one model, but there are others, as the noble Lord would acknowledge. It is right to push us to go further, but what sets this plan apart is not just its level of ambition and its recognition that all is not right in the world but that it is setting out how we will get there. However, I welcome the transparency and leadership which is attached to this—which noble Lords have called for. This plan merits a lot of attention and support. I shall be pleased to discuss it in this Chamber further.

[Baroness Swinburne (Con)]

My Lords, I too recognise that this plan is a really good step forward in terms of the long-term plan for cancer sufferers. Many of our families have been touched by this awful disease, which is many and varied. However, I would like to focus on the innovation and research side of this, our speed of uptake within the NHS across the United Kingdom and how quickly, relative to other places in the world, we get some of the testing that is available out to our UK nationals.

A test called an Oncotype DX test, which is used to determine whether or not it is suitable for breast cancer sufferers to have chemotherapy, has recently been brought to my attention. In many cases, people can avoid chemotherapy if the test is actually telling the clinician that it is not necessary. In fact, the majority of patients with a particular type of breast cancer will not need chemotherapy, and that test will tell them and identify them.

The reality is that that test was available in the US from 2004. It was adopted by NICE in its guidelines in the UK in 2015. It is only now being widely adopted in the NHS across the whole country, rather than just in specialist teaching hospitals. That speed of adoption means that many people are actually having unfortunate treatment that they may not have required.

Therefore, I urge the Minister to look at how quickly we adopt these new genomic tests and how quickly we can actually improve that patient path for each and every patient. This was personalised medicine that was designed 20 years ago and we are only just starting to see it roll out nationally.

[Baroness Merron (Lab)]

The noble Baroness makes a very good point, particularly as we are in what I regard as a whole new area of scientific and technological advancement, and we have the chance to harness it.

In general terms, I can say to the noble Baroness that where, for example, there are regulatory problems with getting new treatments out there, we are working to remove all those blocks. That work is going on.

With regard to genomics, the plan does talk about routine genomic testing to match patients to targeted therapies and trials, and it also talks about investment in AI-guided radiotherapy, in cell therapy and in novel immunotherapies. There is also going to be the establishment of a cancer trial accelerator programme by next year, to increase trial access and speed.

My last point, which I hope will be helpful, is that six national research priorities are established, including early detection, mRNA vaccines, rare cancers and paediatric therapies. I take the point that the noble Baroness is making. The cancer plan addresses that, as well as seeking to remove blocks that should not be there.